BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
FXYD4
,
T cell receptor signaling pathway
,
Pseudomonas infection
,
Retina
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
chymotrypsinogen
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Trypsinogen and chymotrypsinogen: potent anti-tumor agents.
Ultra-rapid glutathionylation of chymotrypsinogen in its molten globule-like conformation: A compari…
Evidence that the Bowman-Birk inhibitor from Pisum sativum affects intestinal proteolytic activities…
Doxorubicin as a Drug Repurposing for Disruption of α-Chymotrypsinogen-A Aggregates.
The digestive system of the stony coral Stylophora pistillata.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Pancreas Volume in Preclinical Type 1 Diabetes
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ